Peer Review, UGC Care
A QSAR study of some Phenoxyacetamide derivatives as a MAO-A inhibitor
View PDF

Keywords

Antipyretic syrup, Stability, Assay of paracetamol syrup

How to Cite

Bais, K. L., Lal, L. ., Mafidar, R. ., Singh, A. ., Mathur, R. ., M. Bhowmick, & Rathi , J. C. . (2018). A QSAR study of some Phenoxyacetamide derivatives as a MAO-A inhibitor. International Journal of Research and Development in Pharmacy & Life Sciences, 7(1), 2931 - 2940. https://doi.org/10.21276/IJRDPL.2278-0238.2018.7(1).2931-2940

Abstract

Antidepressants are the most prescribed therapy for depression. The prevailing theory is that antidepressants increase the concentration of one or more brain chemicals (neurotransmitters) that nerves in the brain use to communicate with one another. The neurotransmitters affected by antidepressants are norepinephrine, serotonin, and dopamine. In order to address the need for new MAO inhibitors with less side effects, we can aim compounds previously discovered for their potential as MAOIs. Among them, safinamide was reported to be a potent anti-MAO B agent, and milacemide, which was found to be a potent MAO inhibitor and a prodrug for glycine. The present work deals with the aim because Currentely available MAO inhibitors {Isocarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam), Tranylcypromine (Parnate) etc} develop side effects because they do not selectively for MAO-A and MAO-B. So, the present study is focused to develop potent selective MAO-A inhibitors, to treat depression, that may be of better pharmacological activity with less adverse effect.

https://doi.org/10.21276/IJRDPL.2278-0238.2018.7(1).2931-2940
View PDF

References

John Smith H (2006) Introduction to the Principles of Drug Design and Action, 4th Edition. CRC Press, New York, pp 78-80.

Eggenweiler HMV (1985) Int J Immunopharmacol. 7: 655-660

Gomoll AW, Temple DL (1987) Drug Dev Res. 10: 57-62.

Povl KL, Tommy L, Ulfa H (2004) Text Book of Drug Designand Discovery. Taylor and Franchis Inc, New York, pp 16-20.

Tipton KF (1986). Enzymology of monoamine oxidase. Cell Biochem Funct 4: 79-87.

Rang HP, Dale MM, Ritter JM, Flower RJ (2008) Pharmacology. Churchill Vingstone Elsevier: London, p 174.

Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309. [PubMed: 16552415]

Shih JC, Chen K, Ridd MJ (1999) Monoamine oxidase: From genes to behavior. Annu Rev Neurosci 22:197–217. [PubMed: 10202537]

Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F(2004) Structure and mechanism of monoamine oxidase. Curr Med Chem 11:1983–1993. [PubMed: 15279562]

Youdim MB, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson´s disease and depressive illness. Br J Pharm 147, S287-S296

Geha RM, Chen K, Wouters J, Ooms F, Shih JC (2002) Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling. J Biol Chem 277, 17209-17216.

Guay DR (2006) Am J Geriatr Pharmacother. 4: 330- 39.

Riederer P, Danielczyk W, Grunblatt E (2004) Neurotoxicology. 25: 271.

Fernandez HH, Chen J (2007). J Clin Neuropharmacol. 30: 150.

Johnston JP (1968) some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285e1297.

Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Nat Acad Sci 85: 4934e4938.

Colibus LD, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A (2005) Proceedings of the National Academy of Sciences of the United States of America 102: 12684e12689.

Binda C, Hubálek F, Edmonson DE, Mattevi A (2002) Nature Structural Biology 9: 22e26.

Ma J, Yoshimura M, Yamashita E, Nakagawa A, Ito A, Tsukihara T (2004) J Mol Biol. 338: 103 –114.

Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T (2008) Structure of human monoamine oxidase A at 2.2-_A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci 105 : 5739e5744.

Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A (2007) Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 50: 5848e5852.

Youdim MB, Edmondson DE, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295e309.

Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F. Structure and mechanism of monoamine oxidase. Curr Med Chem. 2004; 11:1983–1993. [PubMed: 15279562]

Edmondson DE, DeColibus L, Binda C, Li M, Mattevi A. New insights into the structures and functions of human monoamine oxidases A and B. J Neural Transm. 2007; 114:703–705. [PubMed: 17393064]

Saura JL, Cesure JM, Da Prada AM, Chan-Palay M, Huber V, Loffler G, Richard JG (1994) Neuroscience. 62 : 15e30.

Bortolato M, Chen K, Shih AS (2008) Monoamine oxidase inactivation: from pathophysiology to therapeutics. Ad. Drug Deliv Rev 60: 1527e1533.

Da Prada M, Zürcher, G; Wüthrich, I, Haefely, W EJ (2002) Neural Transm. 26, 31

Binda C, Newton-vinson P, Hubálek F, Edmondson DE, Mattevi A (2002) Structure of human monoamineoxidase B, a drug target for the treatment of neurological disorders. Nature Structural Biology 9: 22-26.

De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A (September 2005).

"Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B" Proc Natl Acad Sci U S A. 2005 Sep 6; 102(36): 12684–12689.

S.Y. Son, J. Ma, Y. Kondou, M. Yoshimura, E. Yamashita, T. Tsukihara, Structure of human monoamine oxidase A at 2.2-_A resolution: the control of opening the entry for substrates/inhibitors, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5739e5744.

J.L. Saura, J.M. Cesure, A.M. Da Prada, M. Chan-Palay, V. Huber, G. Loffler, J.G. Richard, Neuroscience 62 (1994) 15e30.

Chapman, A.G.; Hart, G.P. Anticonvulsant drug action and regional neurotransmitter amino acid changes. J. Neural Transm. 1988, 72, 201–212.

Silverman, R.B.; Nishimura, K.; Lu, X. Mechanism of inactivation of monoamine oxidase-B by the anticonvulsant agent milacemide (2-(n-pentylamino)acetamide). J. Am. Chem. Soc. 1993, 115, 4949–4954.

Wei Shen, Shian Yu, Jiaming Zhang, Weizheng Jia and Qing Zhu. Synthesis and Biological Evaluation of 2-Phenoxyacetamide Analogues, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors. Molecules 2014, 19, 18620-18631; doi:10.3390/molecules191118620.

Sliwoski, G. et al. (2014) Computational Methods in Drug Discovery. Pharmacol. Rev. 66, 334–395.

Banks MN, Houston JG. High throughput screening for lead discovery. In: Donald JA, ed. Burger's Medicinal Chemistry, Drug Discovery and Development. 6th Ed. USA: Wiley Publications, 2010: 38-67.

Borman S. New QSAR techniques eyed for environmental assessments. Chem Eng News 1990; 68: 20-23.

Hansch C, Leo A, Mekapati SB, et al. QSAR and ADME. Bioorg Med Chem 2004; 12: 3391–3400.

Kohli DV, Sharma MC, Sahu NK, et al. 2D-QSAR studies of some 1, 3, 4-thiadiazol-2-yl-azetidin-2-one as antimicrobial agents. Dig J Nano Biostru 2009; 4: 339-347.

Hansch C (1969) A quantitative approach to biochemical structure activity relationships. Acc Chem Res 2: 232-2

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Copyright (c) 2020 Array

Downloads

Download data is not yet available.